Introduction
The tumor suppressor gene TP53 (OMIM no. 191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000) . Somatic TP53 gene alterations are frequent in most human cancers and germline TP53 mutations predispose to a wide spectrum of early-onset cancers (Li-Fraumeni (LFS) and Li-Fraumeni-like syndromes (LFL)) (Hainaut and Hollstein, 2000) .
In contrast to other tumor suppressor genes that are mainly altered by truncating mutations, the majority of TP53 mutations are missense substitutions (75%). Other alterations include frameshift insertions and deletions (9%), nonsense mutations (7%), silent mutations (5%) and other infrequent alterations (Olivier et al., 2002) . Since initial studies by Soussi and co-workers (Ory et al., 1994) , it is recognized that different forms of mutant p53 proteins may have different functional and biological effects. About 30% of TP53 missense mutations found in cancer correspond to nucleotide substitutions at highly mutable CpG dinucleotides, at codons encoding residues that play essential structural and chemical roles in the contact between the p53 protein and specific DNA sequences that constitute the p53 response elements (p53-RE) (Hainaut and Hollstein, 2000) . These mutations result in a very significant loss of DNA binding activity and transactivation capacity (Ory et al., 1994) . However, many other residues are also the target of missense mutations, which may differ in their effects on p53 protein structure and activity. In the past 10 years, systematic data have been generated on the functional impact of TP53 missense mutations. In particular, experimental assays have been performed in yeast and human cells to measure various properties including: (1) transactivation activities (TA) of mutant proteins on reporter genes placed under the control of p53-RE; (2) induction of cell-cycle arrest or apoptosis; (3) dominantnegative effects (DNE) over the wild-type protein; (4) temperature sensitivity; (5) activities of mutant proteins that are independent and unrelated to the wild-type protein (gain of function (GOF)). Results from these functional assays have recently been integrated into the International Agency for Research on Cancer (IARC) TP53 database (http://www-p53.iarc.fr/). This database provides structured data and analysis tools to study TP53 mutation patterns in specific cancers and to investigate the functional and clinical impact of mutations. It contains all TP53 gene variations reported in human cancers and populations, with annotations related to the clinical and pathological characteristics of tumors, and demographics, carcinogen exposures and family history of patients. The integration of standardized annotations on the functional impact of missense mutations provides a powerful framework for the analysis of 'functional' patterns of mutations in cancers and the detection of genotype/phenotype associations.
In this review, we exploit the annotations of the IARC TP53 database to summarize the current knowledge on how mutagenesis and biological selection of mutations with specific functional characteristic may explain the pattern of mutations observed in human cancers. Based on these functional considerations, we discuss the genotype-phenotype correlations observed in patients with inherited germline TP53 mutations, as well as the significance of somatic TP53 mutations for predicting cancer progression, response to therapy and outcome.
Somatic mutation patterns: roles of mutagenesis and biological selection
Most TP53 mutations found in human cancers are missense substitutions resulting from single-nucleotide substitutions (SNS) that cluster within the DNAbinding domain of the protein. These mutant proteins often accumulate in the nucleus of tumor cells and are retained in distant metastasis. Moreover, the most frequent mutants have been shown to be capable of cooperating with oncogenes for cellular transformation (Hinds et al., 1990) . These observations have lead to the hypothesis that missense mutations are preferentially selected in cancers because they carry some specific prooncogenic functions (GOF). However, if the expected number of missense mutations within exons 5-8, encoding the DNA-binding domain, is calculated, it is comparable to the observed frequency in cancer. Indeed, among 1567 possible SNS within exons 5-8, 1150 (73.4%) would produce missense mutations, of which 999 (86.8%) have been found in cancer and account for 87.9% of all SNS reported in cancer (Table 1 ). All possible nonsense mutations within exons 5-8 have been found in cancer and are twice more frequent in cancer (7.2%) than expected (3.7%), whereas possible silent mutations are 4-5 times less frequent in cancer than expected (Table 1 ). The selection of nonsense mutations in cancer is thus stronger than the one of missense mutations, whereas silent mutations are counter-selected. These observations suggest that loss of function is a strong factor of selection.
Although missense mutations do not seem to be strongly selected in cancer, some mutants are more frequent than expected. Of the 1150 possible missense mutants, nine account for 30% of missense mutations found in cancers (Olivier et al., 2002) . The frequency of specific mutants can be analysed in relation with their probability of occurrence (based on intrinsic nucleotide substitution rates calculated by Lunter and Hein, 2004) and functional impact (based on TA assessed in yeast assays on eight different p53-RE by Kato et al., 2003) , with new scatter plot graphs that have been implemented in the IARC TP53 database (Figure 1 ). These graphs show that frequent mutants are those associated with high substitution rates and complete loss of TA (Figure 1a and b). For example, transitions at CpG sites are expected to be the more frequent because of their high intrinsic mutagenicity. There are 34 possible missense mutations resulting from transitions at CpG sites within exons 5-8. However, only seven are frequently observed in cancers. These mutants show a complete loss of TA, whereas the 27 rare mutants retain significant TA on one or more p53-RE. Thus, mutagenicity and loss of TA appear to be the main driving forces that shape TP53 mutation patterns.
P53 transcriptional activity relies on the formation of tetramers (dimers of dimers). Mutant proteins may interfere with wild-type p53 by forming hetero-oligomers less competent for specific DNA binding. The capacity of mutant proteins to interfere with the wildtype form has been studied in yeast and human cell assays in various settings. Since the first systematic study performed in yeast on 35 mutants (Brachmann et al., 1996) , data have been produced on more than 200 mutants, showing that DNE correlate with cancer frequency, but that DNE may be promoter-and celltype dependent. A recent analysis of the IARC TP53 database with a group of 117 mutants that were analysed for DNE on p53-RE from WAF-1 and RGC promoters confirmed that the proportion of DNE mutants was indeed correlated with frequency of occurrence in sporadic cancers (data not shown). DNE may thus play a significant role in the selection of mutation in addition to TA and may explain why missense mutant hotspots are more frequent than nonsense mutations (Figure 1a and b) .
In addition to loss of TA and DNE, acquisition of oncogenic GOF activities has been proposed to play a role in the selection of mutations. Studies in mouse models of LFS have reported evidence of GOF for R175H and R273H mutants (Lang et al., 2004; Olive et al., 2004) . Tumors in these knock-in mice were more metastatic or were arising in different tissues compared 
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A Petitjean et al with knockout mice. Interference with p63/73 and increased cell proliferation was suggested to be the underlying molecular mechanisms. In human cells, various GOF properties have been studied, including activation of genes normally unaffected or repressed by wild-type p53, interference with other transcription factors and resistance to specific drugs. However, most experimental data on GOF have been generated with 'hotspot' mutants and no systematic study has been performed that would allow a global analysis of cancerrelated mutants toward their GOF properties. Thus, there is no clear evidence for the impact of a GOF effect on the frequency of p53 somatic mutations in cancer.
The role of mutagenesis in shaping mutation patterns is best illustrated by the example of lung cancer. Instead of the classical hotspots found in most cancers (transitions at CpG sites at codons 175, 248 and 273), specific hotspots are observed in lung cancers ( Figure 1c ). These hotspots are due to G>T transversions that have been shown to be caused by the presence of benzo(a)-pyrene diol epoxide (BPDE) adducts on guanines at these codons (Denissenko et al., 1996) . BPDE is the main metabolite of benzo(a)-pyrene, one of the most potent carcinogens present in high quantity in tobacco smoke. In lung tissue from smokers, the actual nucleotide substitution rate for these mutants is thus expected to be higher than the one estimated from endogenous processes. The lung hotspots are all defective for TA with less than 20% of wild-type activity on all p53-RE ( Figure 1d ). Another site of adduct formation by BPDE is the third base of codon 267, but the resulting mutation would not produce an amino-acid change. This mutation has been reported only once in a breast tumor sample. These results show that both mutagenesis and selection of loss of TA is shaping the patterns of mutation observed in lung cancer. In other tissues where non-classical hotspots are observed (such as nonmelanoma skin cancers or bladder carcinoma), similar mechanisms involving other carcinogens or specific mutagenic conditions are suspected to be involved. Mutants resulting from an SNS are represented as dots, which are color-and shape-coded according to the functional impact of the mutation, and located on the x axis according to their frequency in cancer and on the y axis according to nucleotide substitution rates that produced the mutation. (a and c) Missense, nonsense and silent mutations reported in all cancer (a) or in non-small-cell carcinomas of the lung (c). (b and d) Missense mutations can be further color-and shape-coded according to their transactivation capacity (based on a classification derived from functional assays in yeast). Detailed functional annotations for each specific mutant can be downloaded at http://www-p53.iarc.fr/Mutations.html.
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Polymorphisms in the TP53 gene
The list of polymorphisms (SNP) along the TP53 gene has considerably grown these last years, because of large-scale genome sequencing (http://www-p53.iarc.fr/ Polymorphism1.html). The most extensively studied SNP (SNP72) is a G/C variation at the second position of codon 72 in exon 4, leading to Arg72 or Pro72 protein variants. Sharp ethnic differences are observed for this SNP, the Arg72 variant being more prevalent in Caucasians, whereas the Pro72 variant is more prevalent in Chinese and African-Americans (Beckman et al., 1994; Langerod et al., 2006a) . Residue 72, although not conserved, is located within a proline-rich region and may affect the structure of the putative SH3-binding domain in p53. Several functional differences have been reported between the Arg72 and Pro72 variants. Arg72 was shown to be more efficient in inducing apoptosis, a property that correlated with a greater capacity to interact with MDM2 which facilitate nuclear export and mitochondrial localization (Dumont et al., 2003) . In contrast, the Pro72 variant was found to be more efficient in inducing cell-cycle arrest (Pim and Banks, 2004) and DNA repair (Siddique and Sabapathy, 2006) . Other differences include the ability to bind components of the transcriptional machinery, to activate transcription, and to repress the transformation of primary cells (Thomas et al., 1999) . The protein with Arg72 was also found to be more efficiently targeted for degradation by the E6 protein of human papilloma virus (HPV)16, suggesting that individuals homozygous for Arg72 may be at higher risk of HPV-related cervical cancers (Storey et al., 1998) . However, most population-based studies have so far failed to confirm this hypothesis (Helland et al., 1998; Klug et al., 2001; Koushik et al., 2004) .
From the differences in functional properties, one may expect an impact of this SNP72 on cancer susceptibility, response to chemotherapeutic treatments and/or patients outcome. Numerous studies have analysed the impact of SNP72 on cancer risk but results have been contradictory and no clear consensus has been reached. For the impact on cancer outcome, one study on advanced head and neck squamous cell carcinoma (HNSCC) has shown that patients carrying a wild-type Arg72 variant have a better outcome in response to chemotherapy than those carrying a wildtype Pro72 variant (Sullivan et al., 2004) . However, as almost half of HNSCC carry a somatic TP53 mutation, the effect of such a mutation must be taken into account. Marin et al. (2000) were the first to report that in squamous cell carcinomas (SCC) TP53 mutations were more frequent in tumors of Pro/Arg heterozygous patients compared with Arg/Arg homozygous patients, with mutations occurring on the Arg allele and loss of heterozygosity (LOH) affecting the Pro allele. They proposed that the selective mutation of the Arg allele may be explained by the fact that SNP72 can be an intragenic modifier of mutant p53 behavior. Indeed, they showed that Arg72-containing alleles were more potent in neutralizing p73-induced activity. The role of p73 in this selection was emphasized by the fact that in breast adenocarcinomas, that did not express p73, mutations did not occur preferentially on the Arg allele (Marin et al., 2000) . Inhibition of drug-induced p73-dependent apoptosis by mutants has been shown to correlate well with the response to chemo-radiotherapy treatment of HNSCC patients, carriers of a 72Pro mutant showing longer overall and progression-free survivals (Bergamaschi et al., 2003) . Based on these results, several studies have tried to use solely SNP72 as a prognostic factor but showed conflicting results (Xu et al., 2005; Kochethu et al., 2006; Santos et al., 2006; Wegman et al., 2006) .
Selective mutation of the Arg allele has been observed by others in HNSCC (Bergamaschi et al., 2003; Schneider-Stock et al., 2004) and non-small-cell lung cancer (Nelson et al., 2005) , but also in breast cancer (Langerod et al., 2002; Bonafe et al., 2003) . Moreover, other studies showed that TP53 mutation preferentially occurred on the Pro72 allele in advanced ovarian carcinoma (Wang et al., 2004) , or did not find any difference between the genomic status at codon 72 and the presence of TP53 mutation in colorectal cancer (Langerod et al., 2002) . Thus, the significance and tissue specificity of the preferential expression of a mutated Arg72 allele remain to be clarified. Interestingly, Tada et al. (2001) reported that preferential mutation of the Arg allele was only true for mutants, which were not DNE. The nature of mutation may thus add a level of complexity to this question.
Another polymorphism, the 16 bp duplication in intron 3 (DIN3), has been found to be associated with increased risk of colorectal cancer in a case-control study and correlated with a reduced level of TP53 mRNA in lymphoblastoid cell lines (Gemignani et al., 2004) . However, because of a strong linkage disequilibrium (LD) between DIN3 and SNP72, it cannot been determined from these experiments whether DIN3 alone influences mRNA stability or if this effect requires the Pro72 variant. In another study, haplotypes for DIN3, SNP72 and intron 6 G>A correlated with higher apoptotic indices and DNA repair capacity in lymphoblastoid cell lines (Wu et al., 2002) .
These experimental data give additional clues for a biological effect of TP53 polymorphisms on p53 function and point out the fact that haplotypes may provide more relevant information than SNPs. In a recent study, extensive re-sequence analysis of all exons, evolutionarily conserved intronic regions, 6 kb of the promoter region and spaced regions up to 50 kb in either direction of TP53 in 94 healthy Norwegian women, showed that LD extended across the entire TP53 coding region including the two neighboring genes, ATP1B2 and WDR79 (Langerod et al., 2006a) . SNP72 was shown to reside on several common haplotypes and, in non-African populations, a significant north-south gradient for the Arg allele was found, with an increase in allele frequency in association with distance from the equatorial plane. This latter observation suggests that this allele could have undergone selection after the dispersion out of Africa. Analyses of 18 SNPs in the
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A Petitjean et al TP53 region and neighboring genes on the same LD block in 2700 breast cancer cases and 3400 controls from Norway and Poland, showed no individual SNP in TP53 to be significantly associated with risk of breast cancer (paper submitted). However, significant and consistent associations with two linked SNPs in the 5 0 neighboring gene WDR79 was found. Stratification of tumors by estrogen (ER) and progesterone receptor (PR) status showed these increases in risk to be limited to ER expressing tumors. From the data reviewed above, it is clear that more systematic studies are needed to clarify the impact of both SNP72 and the various TP53 haplotypes on cancer outcome, taking into account the genotype of patients, and the LOH and TP53 mutation status of tumors.
Phenotype-genotype correlations of germline mutations
TP53 germline mutations are associated with LFS and LFL (Malkin et al., 1990) . TP53 germline mutations have also been reported in individuals with no family history or with a family history not fulfilling LFS or LFL definitions (Olivier et al., 2003) . The most frequent cancers associated with TP53 mutations are breast cancer, bone and soft tissue sarcomas, brain tumors and adrenocortical carcinomas (ADC) (Wong et al., 2006) . Other less frequent cancers include leukemia, stomach cancer and colorectal cancer.
Genotype-phenotype correlations have been reported in TP53 germline mutation carriers (Birch et al., 1998; Olivier et al., 2003) . Missense mutations located within the DNA-binding loops of the protein were found associated with a higher prevalence of brain tumors and an earlier age at onset of breast cancers, whereas missense mutations outside the DNA-binding loops were associated with a higher prevalence of ADC (Olivier et al., 2003) . Using the new functional annotations integrated in the IARC TP53 database, the mean age at onset of tumors in confirmed carriers of missense mutations was compared between partially functional and non-functional missense mutants (based on TA) for cancers where at least four tumors with age data was available. The mean age at onset of breast and colorectal tumors in carriers of a non-functional mutation was significantly lower than the one for carriers of partially functional mutation (Table 2) . Thus, the penetrance of a mutation may be related to its degree of loss of TA, at least in some tissues. The notion that loss of function is in itself sufficient for causing LFS is substantiated by the fact that a large deletion encompassing the whole TP53 gene has been reported in an LFS family (Bougeard et al., 2003) .
The fact that transcription-competent mutations can be found in cancer families is surprising. In such families, 7/20 carried a transcription-competent mutation that is predicted to be deleterious based on sequence conservation. It is thus possible that loss of an activity independent of TA, or not captured by the yeast assays, contributes to the observed phenotypes. It is also possible that mutations in other genes may contribute to the cancer phenotype. Indeed, in one family, the TP53 mutation (N210Y) was concomitant with a truncating mutation in APC (Zajac et al., 2000) . The phenotype in this family was classical FAP (familial adenomatous polyposis syndrome, associated with APC mutation), but with a more severe phenotype than expected from the associated APC mutation. Recently, a polymorphism in the MDM2 gene (SNP309) has been shown to influence the age at onset of tumors in TP53 mutation carriers in a gender-and hormone-dependent manner (Bond et al., 2004 (Bond et al., , 2006 Bougeard et al., 2006) . These examples show how a combination of mutations with intermediate penetrance in two tumor suppressor genes may result in atypical phenotypes. Families with a partially functional TP53 mutation may thus carry another intermediate penetrance mutation that act in synergy with TP53 to promote cancer in tissues that are less typical or occur at different age than the one in families that carry high-penetrance TP53 mutations.
Another example of atypical phenotype linked to a specific TP53 germline mutation has been reported in Brazilian families. A specific mutation, R337H (CGC to CAC), located within the oligomerization domain of p53 has been first reported in children with ADC but not documented in familial history of other cancers (Ribeiro et al., 2001) . Structural and functional studies have identified that R337H mutant had a pH-dependent defect, making the protein inactive only in conditions of increased intracellular pH (DiGiammarino et al., 2002) . It was postulated that replacement of Arg by His at codon 337 in the dimerization motif of p53 alters hydrogen bonding between two p53 monomers, hampering dimerization and consequently specific DNA binding at pH8. This observation has led to the speculation that R337H may predispose to cancer development only in tissues in which a rise in intracellular pH is a major growth or survival regulatory signal. Such a rise in pH occurs in apoptotic cells and may play a role in the extensive tissue remodeling that occurs through selective apoptosis in adrenal cortical glands during pre-and post-natal development. The authors postulated that it may explain why this conditional mutant might only predispose to ADC. However, in a study on 45 Brazilian families selected for their compliance to LFS/LFL clinical definitions, we found the R337H mutant in six LFL families (Achatz et al., 2007) . In one breast tumor, from a R337H carrier, Tumors in confirmed carriers of a germline TP53 mutation reported in the IARC TP53 database (R11, October 2006).
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A Petitjean et al of which tumor material was available, LOH was demonstrated. The spectrum of cancers in these families was similar to the one of LFL families carrying other types of TP53 mutations, with a high prevalence of breast cancers and sarcomas, and only two families with ADC cases. Thus, the phenotype associated with R337H is not restricted to ADC. In fact, in yeast assays, this mutant showed defect in oligomerization and partial loss of function. The fact that this mutant retains significant activity (TA and possibly others) that may depend on cellular conditions may make it highly susceptible to gene-gene and gene-environment interactions, which may explain phenotypic variations observed in different series of patients.
Mutation and prognosis: lessons from breast cancer
Several studies have investigated the predictive value of TP53 mutation status for tumor response to treatment and patient outcome in various cancers. However, different clinical and methodological settings have been used and the results have often been heterogenous and contradictory. The vast majority of studies have relied on immunohistochemistry (IHC) to assess p53 alterations. This approach is, however, a poor surrogate for gene mutation detection, as many mutations do not lead to protein accumulation, and as accumulation of wildtype p53 may also occur in the absence of gene mutation. Hence, the use of IHC leads to an unacceptable number of misclassified cases and to a greater inter-study variability. By contrast, in studies that have screened TP53 mutations by gene sequencing to precisely identify the mutation, the presence of a mutation has been correlated with a shorter survival or a poor response to treatment in several cancers (comprehensive list of studies available at http://www p53.iarc.fr/Somatic.html). Moreover, a number of studies have described specific types of mutation that were associated with a worse prognosis compared with other mutations. This is the case for mutations within the DNA-binding motifs that have been repeatedly associated with shorter survival or poor response to chemotherapy in several types of cancer.
In breast cancer, more than 20 studies have analysed the prognostic or predictive value of TP53 mutation. Almost all of them have shown that TP53 mutation was clearly associated with bad prognosis, mutations at residues involved in DNA contacts often being of worse prognosis. However, it was not clear from these studies whether TP53 is a factor of prognosis independently of other clinicopathological factors, and there is no clear consensus on the specific type of mutations carrying a worse prognosis, as different classifications of mutations have been used and the comparison of individual mutations was limited by a lack of statistical power. To assess through a more powerful analysis whether the identification of TP53 mutation presents a real benefit over currently available factors of prognosis (such as tumor size, node status, and ER and PR contents), we have recently collected and pooled clinical and molecular data on 1794 European breast cancer patients who were followed up for at least 10 years and whose tumors were screened for somatic TP53 gene mutation. Results from this large cohort showed that TP53 mutation was an independent factor of poor prognosis, and that missense mutations located within the DNA-binding motifs had a similar prognostic value than non-missense mutations, the later being associated with the worse outcome (Olivier et al., 2006) . The non-missense mutations in this series were mostly truncating mutations predicted to result in the absence of protein expression, hence a clear loss of function. Thus, loss of function may be sufficient for the poor prognosis of missense mutations located within the DNA-binding motifs.
When classified with annotations in the IARC TP53 database, the majority of missense mutations in the breast cancer series were TA incompetent and predicted as deleterious according to inter-species protein sequence conservation (Olivier et al., 2006) . Thus, the difference in prognosis observed between missense mutations located outside the DNA-binding motifs and those located within the DNA-binding motifs could not be explained by a difference in TA. With new data available on DNE (Dearth et al., 2006) , we could reannotate 160 mutants out of 235 from the breast series for their capacity to exert strong DNE on both WAF1 and RGC p53-RE. Among 133 mutants located within the DNA-binding motifs, 110 were DNE (83%), whereas among 27 mutants located outside the DNAbinding motifs, seven were DNE (26%). The difference in prognosis may thus be related to the DNE capacity of mutants, an interesting observation that would require to be confirmed by further studies. It also remains to be determined whether GOF may be implicated, but experimental functional data on a larger spectrum of mutants would be needed to perform such analysis.
If TP53 mutation status has a clear prognostic value on its own, its value against other molecular markers of prognosis, which are validated or under testing has not been investigated thoroughly. In a large study including women with node-negative breast cancer, TP53 mutation status was shown to be useful to identify women at higher risk of disease recurrence and death when their tumor had ERBB2 amplification (Bull et al., 2004) . More recently, expression profiling using micro-arrays for tumor classification has received a lot of attention. The first study that identified different subtypes of tumors based on their expression profiles showed that these profiles were associated with differences in clinical outcome and that TP53 gene mutation clustered with the profiles associated with worst outcome (Sorlie et al., 2001) . Then, the question of whether gene expression profiles offer better prognostic information in patients with long-term follow-up was addressed (Langerod et al., 2006b) . Both univariate and multivariate analysis showed that TP53 mutation status and tumor size were the strongest predictors of breast cancer survival when expression subgroups were not included, but gene expression-based classification and tumor size were the most significant and independent predictors of survival
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A Petitjean et al when all parameters were analysed. The TP53 mutation status showed strong association with the 'basal-like' gene expression subgroup, and these tumors had a characteristic gene expression pattern. Using a different set of genes, Miller et al. (2005) have identified an expression signature for TP53 mutation status in human breast cancer that is a good predictor of patient survival. Overall, these results strongly support the fact that TP53 mutations have a prognostic value in various groups of breast cancer patients, the associated risk of dying from breast cancer ranging from 2 to 5.
Conclusion
In the early 1990s, the rapid accumulation of data on TP53 mutations in human cancer raised high expectations for clinical exploitation. However, the use of IHC as a surrogate for genetic analysis has confused the scientific and medical community by producing contradictory results. From the currently available data on the functional impact of specific mutations and on large series of tumors screened for TP53 gene alterations, it is clear that the precise identification of the genetic alteration is required for the correct interpretation and analysis of TP53 status in relation to tumor phenotype or patient outcome. Moreover, mutation analysis should also include assessment of the haplotype of the allele harboring the mutation as well as of the loss of the residual, wild-type allele (LOH). Performing such analyses in a streamlined, cost-effective manner compatible with clinical application will require further technological developments. Until recently, polymerase chain reaction-based prescreening methods (singlestranded conformational polymorphism, denaturing gradient gel electrophoresis and its variations, denaturing high performance liquid chromatography) followed by DNA sequencing, have been the gold standards for gene mutation identification, but they are labor-intensive, thus not suitable for clinical practice. In addition, they do not allow to easily reconstruct wild-type and mutant haplotypes and are not suitable for assessing LOH. New techniques have been developed recently that may be more easily implemented for routine use, such as microarray-based methods (Affymetrix, APEX (Le Calvez et al., 2005) ).
In terms of future research, the focus should be on developing TP53 mutation studies in the context of clinical trials. Large trials including hundred of patients randomly allocated to different treatment protocols are necessary to provide sufficient statistical power to determine the exact impact of TP53 mutations, not only on overall survival but also on response to treatment. Such data will also help to delineate in which tumors and clinical context TP53 may represent a specific target for new therapeutic approaches. Finally, studies on cancer syndromes associated with TP53 germline mutations may provide a wealth of novel and important information on the mechanisms that regulate the penetrance of TP53 mutations, as well as on geneenvironment interactions that may either maximize or minimize the clinical impact of TP53 mutations. There is mounting evidence that polymorphisms in gene regulating the TP53 pathway, including MDM2 and AKT1, are potential modifiers of TP53 gene functions (Bond et al., 2004; Harris et al., 2005) . Understanding the nature and mechanisms of these modifying effects, as well as the biological context in which they occur, will open new perspectives for approaches aimed at controlling the clinical impact of TP53 mutations.
